Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yu-Chen Enya Chen"'
Autor:
Yu-Chen Enya Chen, Melinda Burgess, Sally Mapp, Peter Mollee, Devinder Gill, Antje Blumenthal, Nicholas A. Saunders
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Targeted antibody therapies improve outcomes for chronic lymphocytic leukemia (CLL) patients. However, resistance often develops. We have previously shown that resistance to therapeutic antibodies, by monocyte derived macrophages (referred to as nurs
Externí odkaz:
https://doaj.org/article/b9578f6fa5824a12a011388f3633dbd1
Autor:
Devinder Gill, Sally Mapp, Melinda Burgess, Peter Mollee, Nicholas A. Saunders, Yu Chen Enya Chen
Publikováno v:
Leukemia & Lymphoma. 61:2738-2742
Antibody therapies are important treatment options for Chronic lymphocytic leukemia (CLL). Monocyte-derived-macrophages (MDMs) are thought to be a major immune effector that clears leukaemic cells ...
Autor:
Peter Mollee, Sally Mapp, Nicholas A. Saunders, Devinder Gill, Antje Blumenthal, Melinda Burgess, Yu-Chen Enya Chen
Publikováno v:
Leukemia. 34:451-461
Fcγ receptor (FcγR) signalling in monocyte derived macrophages from chronic lymphocytic leukaemia (CLL) patients is poorly understood. This signalling pathway is the key determinant of the ability of the macrophages to respond to therapeutic antibo
Autor:
Yu-Chen, Enya Chen, Melinda, Burgess, Sally, Mapp, Peter, Mollee, Devinder, Gill, Antje, Blumenthal, Nicholas A, Saunders
Publikováno v:
Leukemia. 34(2)
Fcγ receptor (FcγR) signalling in monocyte derived macrophages from chronic lymphocytic leukaemia (CLL) patients is poorly understood. This signalling pathway is the key determinant of the ability of the macrophages to respond to therapeutic antibo
Autor:
Yu-Chen Enya Chen, Sally Mapp, Nicholas A. Saunders, Malcolm I. Burgess, Antje Blumenthal, Peter Mollee, Devinder Gill
Publikováno v:
Oncogene. 40:1203-1203
Since publication of the article the authors realised one of the author names was incorrect. Y.C.E. Chen was incorrectly written as U.C.E. Chen. This has now been corrected in the PDF and XML.
Autor:
Nicholas A. Saunders, Devinder Gill, Melinda Burgess, Yu-Chen Enya Chen, Antje Blumenthal, Peter Mollee, Sally Mapp
Publikováno v:
Blood. 132:3128-3128
There is a continued reliance on antibody therapies for treating chronic lymphocytic leukaemia (CLL). Whilst the inclusion of antibody therapies in many standard treatment regimes results in good outcomes, acquired resistance remains a significant cl
Autor:
Hui-Hsien Chou, Ping-Yi Wu, Cheng-Pu Sun, Tzu-Hui Wu, Chun-Chi Chen, Mi-Hua Tao, Yu-Chen Enya Chen, Karl-Dimiter Bissig, Yao-Ming Shih
Publikováno v:
Scientific Reports
Selection of escape mutants with mutations within the target sequence could abolish the antiviral RNA interference activity. Here, we investigated the impact of a pre-existing shRNA-resistant HBV variant on the efficacy of shRNA therapy. We previousl